Login to Your Account


Biogen Inc. unveiled plans Tuesday to sharpen its focus on neurology by breaking its hemophilia business out into a new publicly traded company. The tax-free transaction is expected to be a boon for Biogen shareholders, but analysts were split on its broader implications.

more »

Our Habitat for All Things Science
B-cell receptor could be antitumor target

Peptibodies targeting the B-cell receptor might provide a cancer therapy that is personalized to specific tumor cells but can be produced in a relatively automated fashion, making the production of such individualized therapy a realistic possibility.

Preclinical work describing the approach appeared in the April 25, 2016, online issue of the Proceedings of the National Academy of Sciences.

B cells have a truly unique surface protein – their business end, the B-cell receptor or idiotype, which is different on every B cell.

On B cell-derived tumor cells, that READ MORE »


Partners in Focus